TennCare - As introduced, requires a TennCare health benefit plan renewed or issued on or after July 1, 2025, by a health insurance carrier to provide coverage and reimbursement for biomarker testing for preeclampsia in pregnant women. - Amends TCA Title 56; Title 63; Title 68 and Title 71.

SB 205 requires TennCare health benefit plans (for Tennessee's Medicaid program) renewed or issued after July 1, 2025, to cover and reimburse FDA-approved biomarker testing for preeclampsia in pregnant women. This directly affects pregnant TennCare enrollees, health insurance carriers providing TennCare plans, and healthcare providers who order the tests. The bill mandates coverage only when ordered by a physician following clinical guidelines, using tests that meet FDA standards for detecting preeclampsia biomarkers in blood or tissue. The law takes effect July 1, 2025, with TennCare able to seek federal approval for coverage through CMS waivers.